Clinical Analysis of 122 Cases with Mycoplasma Pneumonia Complicated with Atelectasis: A Retrospective Study

  • De-Quan Su
  • Jin-Fan Li
  • Zhi-Qiang ZhuoEmail author
Original Research



This study aims to explore the clinical characteristics, treatment, and prognosis of mycoplasma pneumonia complicated with atelectasis.


A retrospective analysis was performed on 122 children with mycoplasma pneumonia complicated with atelectasis. These children were hospitalized in the Xiamen Campus of the Pediatric Hospital of Fudan University and the Children’s Hospital of Xiamen between December 2015 and December 2018. A diagnosis was made for each case on the basis of the clinical symptoms and signs, Mycoplasma pneumoniae-specific IgM antibody, and imaging results.


Among the 122 cases with mycoplasma pneumonia complicated with atelectasis, all cases had retractable M. pneumoniae infection, 102 cases underwent fibrobronchoscopic lavage treatment, and all cases were treated with macrolide antibiotics after a definite diagnosis was made. Furthermore, 107 cases improved and were discharged. Follow-up was performed for 3–4 weeks for all patients, and all patients, including the five cases with retractable disease, recovered well.


The major clinical manifestations for M. pneumoniae pneumonia are fever and stimulatory dry cough. Macrolide antibiotics remain the treatment of choice.


Atelectasis Children Clinical characteristics Infectious diseases Mycoplasma pneumoniae Prognosis Treatment 



We thank the participants of the study.


No funding or sponsorship was received for this study or publication of this article. The Rapid Service Fees were funded by the authors.


All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.


De-Quan Su, Zhi-Qiang Zhuo, and Jin-Fan Li declare that they have no conflict of interest.

Compliance with Ethics Guidelines

This study was conducted in accordance with the 1964 declaration of Helsinki and its later amendments and was approved by the Ethics Committee of the Children’s Hospital of Fudan University Xiamen Branch. Written informed consent was obtained from all participants.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.


  1. 1.
    Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175(10):1086–93. Scholar
  2. 2.
    Hu YM, Jiang ZF, Shen KL, Shen Y. Chu Futang practical pediatrics. 8th ed. Beijing: Beijing People’s Medical Publishing Press; 2015. p. 1280–2 (In Chinese).Google Scholar
  3. 3.
    Haccuria A, Michils A, Michiels S, Van Muylem A. Exhaled nitric oxide: a biomarker integrating both lung function and airway inflammation changes. J Allergy Clin Immunol. 2014;134(3):554–9. Scholar
  4. 4.
    Yu H, Côté P, Shearer HM, et al. Effectiveness of passive physical modalities for shoulder pain: systematic review by the Ontario protocol for traffic injury management collaboration. Phys Ther. 2015;95(3):306–18. Scholar
  5. 5.
    Migneault A, Sauvageau S, Villeneuve L, et al. Chronically elevated endothelin levels reduce pulmonary vascular reactivity to nitric oxide. Am J Respir Crit Care Med. 2005;171(5):506–13. Scholar
  6. 6.
    Marini S, Buonanno G, Stabile L, Ficco G. Short-term effects of electronic and tobacco cigarettes on exhaled nitric oxide. Toxicol Appl Pharmacol. 2014;278(1):9–15. Scholar
  7. 7.
    Chiang WC, Teoh OH, Chong CY, Goh A, Tang JP, Chay OM. Epidemiology, clinical characteristics and antimicrobial resistance patters of community-acquired pneumonia in 1702 hospitalized children in Singapore. Respirology. 2007;12(2):254–61. Scholar
  8. 8.
    Shimoda T, Obase Y, Kishikawa R, Iwanaga T. Influence of cigarette smoking on airway inflammation and inhaled corticosteroid treatment in patients with asthma. Allergy Asthma Proc. 2016;37(4):50–8. Scholar
  9. 9.
    Vardavas CI, Anagnostopoulos N, Kougias M, Evangelopoulou V, Connolly GN, Behrakis PK. Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide. Chest. 2012;141(6):1400–6. Scholar
  10. 10.
    Jiang W, Yan Y, Ji W, Wang Y, Chen Z. Clinical significance of different bacterial load of Mycoplasma pneumoniae in patients with Mycoplasma pneumoniae pneumonia. Braz J Infect Dis. 2014;18(2):124–8. Scholar
  11. 11.
    Grabowska-Krawiec P. Contemporary risks of infections by Mycoplasma pneumoniae and Chlamydophila pneumoniae. Pol Merkur Lekarski. 2012;33(197):270–3.PubMedGoogle Scholar
  12. 12.
    Matsuda Y, Chigusa Y, Kondoh E, Ito I, Ueda Y, Mandai M. A case of macrolide-refractory Mycoplasma pneumoniae pneumonia in pregnancy treated with garenoxacin. Case Rep Obstet Gynecol. 2017;2017:3520192. Scholar
  13. 13.
    Rey JW, Deris N, Marquardt JU, et al. High-definition endoscopy with iScan and Lugol’s solution for the detection of inflammation in patients with nonerosive reflux disease: histologic evaluation in comparison with a control group. Dis Esophagus. 2016;29(2):185–91. Scholar
  14. 14.
    Hulman S, Kushner H, Katz S, Falkner B. Can cardiovascular risk be predicted by newborn, childhood, and adolescent body size? An examination of longitudinal data in urban African Americans. J Pediatr. 1998;132:90–7. Scholar
  15. 15.
    Biondi E, McCulloh R, Alverson B, Klein A, Dixon A, Ralston S. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 2014;133(6):1081–90. Scholar
  16. 16.
    Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol. 2011;6(4):423–31. Scholar
  17. 17.
    Ma EL, Wang C, Wang MW. Advances in research on immune-regulatory effects of macrolide antibiotics. World Notes Antibiot. 2003;1:1–4 (In Chinese).Google Scholar
  18. 18.
    Xin DL, Shi DW. Advances in antibiotics treatment of macrolide antibiotics-resistant Mycoplasma pneumoniae pneumonia. Chin J Pract Pediatr Clin. 2013;22:1695–7. Chinese).CrossRefGoogle Scholar
  19. 19.
    Meyer Sauteur PM, Vall Rossurn AM, Vink C. Mycoplasma pneumoniae in children: carriage, pathogenesis, and antibiotic resistance. Curr Opin Infect Dis. 2014;27(3):220–7. Scholar
  20. 20.
    Jin J, Wang LB, Zhang MZ, Zhou BH, Zhi DJ. Clinical features and bronchoscopy treatment for 378 patients of Mycoplasma pneumoniae pneumonia in children. Chongqing Med. 2015;44(34):4815–7. Chinese).CrossRefGoogle Scholar
  21. 21.
    Zhuo Z, Li F, Chen X, Jin P, Guo Q, Wang H. Mycoplasma pneumonia combined with pulmonary infarction in a child. Int J Clin Exp Med. 2015;8(1):1482–6.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pediatric InternalChildren’s Hospital of Fudan University Xiamen BranchXiamenChina

Personalised recommendations